Storey, Dawn Jane

2018-03-29T12:20:29Z

2018-03-29T12:20:29Z

2008

BACKGROUND Fatigue is a common and debilitating problem for cancer patients. It is associated with cancer or its treatment. Evidence suggests fatigue may be prolonged after treatment for some cancers and could be associated with a host systemic inflammatory response. Prostate cancer is the commonest male cancer however little is known about fatigue and its associations in this population.

AIMS To explore the incidence of fatigue and its associations during and after treatment for prostate cancer.

METHODS Four studies were conducted: Study A, was a pilot study which examined fatigue over 3 months after different treatments for localised prostate cancer (radiotherapy, brachytherapy and androgen deprivation, n=45). Study B focussed on fatigue over 12 months after brachytherapy (n=51). Two cross sectional postal surveys explored fatigue in recurrence free prostate cancer survivors (Study C, n=443) and hormone controlled prostate cancer (Study D, n=198). Throughout, fatigue was assessed using the Brief Fatigue Inventory and a case definition of clinically significant fatigue (CSF) was also constructed and applied in Studies A and B.

RESULTS Study A found CSF increased after treatment but returned to baseline 3 months after radiotherapy, whereas it appeared to be prolonged after brachytherapy. CSF was not associated with C reactive protein or interleukin-6. Study B found CSF increased between baseline and 1 month after brachytherapy (6 vs. 29%, p=0.001) and was higher than the non-cancer comparison group (29 vs. 4% p=0.001). CSF returned towards baseline levels by 6 months. There were no baseline predictors of developing CSF. Study C found 29% of recurrence free prostate cancer survivors had fatigue after radiotherapy or radical prostatectomy (33 vs. 22% p=0.024) but it was not independently associated with treatment received after controlling for other factors. 43% of men with hormone controlled prostate cancer had fatigue in Study D.

CONCLUSIONS Fatigue is an important symptom in men treated for prostate cancer but resolves within months of brachytherapy. Almost one third of recurrence free survivors have fatigue but it does not appear to be related to the type of treatment received. Fatigue is most prevalent in men with hormone controlled prostate cancer.

http://hdl.handle.net/1842/29383

The University of Edinburgh

Annexe Thesis Digitisation Project 2018 Block 17

Already catalogued

Fatigue and prostate cancer

Thesis or Dissertation

Doctoral

MD Doctor of Medicine